Jason Fontenot has been appointed chief scientific officer of Seattle cell therapy developer Immusoft. Fontenot most recently worked at Seattle cancer immunotherapy company Juno Therapeutics, which was acquired by Celgene (NASDAQ: [[ticker:CELG]]) earlier this year in a $9 billion deal. Immusoft is researching a way of reengineering the B cells of the body into treatments for diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
